       Document 0595
 DOCN  M9630595
 TI    Gag-specific cytotoxic responses to HIV type 1 are associated with a
       decreased risk of progression to AIDS-related complex or AIDS.
 DT    9603
 AU    Riviere Y; McChesney MB; Porrot F; Tanneau-Salvadori F; Sansonetti P;
       Lopez O; Pialoux G; Feuillie V; Mollereau M; Chamaret S; et al; URA CNRS
       1157 Departement des Retrovirus, Institut Pasteur,; Paris, France.
 SO    AIDS Res Hum Retroviruses. 1995 Aug;11(8):903-7. Unique Identifier :
       AIDSLINE MED/96020091
 AB    The duration of human immunodeficiency virus (HIV-1) infection prior to
       the development of AIDS is variable, and for most patients the exact
       time of infection is not known. A group of 38 HIV-1-infected subjects
       was tested while asymptomatic for comparative cytotoxic lymphocyte
       responses to the Gag and envelope antigens of HIV-1. Twenty of the 38
       patients had no detectable primary cytotoxic T lymphocyte (CTL) response
       to Gag, and this was associated with a relative risk of 1.89 for
       progression to ARC or AIDS during the subsequent 3 to 40 months of
       observation when compared with patients who had Gag-specific CTL
       activity at the beginning of the observation period. In contrast, no
       significant association was observed between envelope-specific cytotoxic
       activity and disease progression. Other patient characteristics,
       including CD4+ T lymphocyte counts and antibody levels to the p24gag
       protein, measured at the start of observation, did not correlate with
       disease progression during the observation period. This suggests that
       the anti-Gag CTL response may be protective during HIV-1 infection.
 DE    Acquired Immunodeficiency Syndrome/ETIOLOGY/*IMMUNOLOGY  *Cytotoxicity,
       Immunologic  CD4-Positive T-Lymphocytes/*IMMUNOLOGY  Gene Products,
       gag/*IMMUNOLOGY  Human  HIV
       Infections/COMPLICATIONS/*IMMUNOLOGY/PHYSIOPATHOLOGY
       HIV-1/*IMMUNOLOGY/METABOLISM  Prognosis  Risk Factors  Support, Non-U.S.
       Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

